United Therapeutics (NASDAQ:UTHR) Announces Earnings Results, Misses Expectations By $0.30 EPS

United Therapeutics (NASDAQ:UTHR) issued its quarterly earnings results on Wednesday. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30), FiscalAI reports. The company had revenue of $832.50 million during the quarter, compared to the consensus estimate of $781.14 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $7.16 earnings per share.

Here are the key takeaways from United Therapeutics’ conference call:

• United Therapeutics reported record third-quarter revenue of $833 million, including record Tyvaso revenue of $504 million. Management attributed growth to sustained demand, stronger commercial execution, higher dosing and expanded field-force reach; October referrals also reached a monthly record.
• A court decision upholding the company’s intellectual property and a settlement with Liquidia remove PH-ILD from YUTREPIA’s label and bar its promotion for that indication. Management expects limited near-term patient switching, while emphasizing new prescriptions and market expansion as the main Tyvaso growth opportunity.
• The planned soft mist inhaler NDA filing has been pushed from year-end 2026 to 2027 after FDA discussions identified a need for additional supporting data, delaying a potential product opportunity.
• Ralinepag’s FDA application remains under review with a June 24, 2027 PDUFA date, but its API supplier has an Official Action Indicated compliance status. The company is pursuing remediation and says it has contingency plans, though the issue could pose a regulatory or supply risk.
• The FDA indicated that bioequivalence data would not be sufficient to support filing the triple oral pill; the company is evaluating alternative development and filing approaches, with no timeline disclosed.

United Therapeutics Stock Up 1.2%

Shares of United Therapeutics stock opened at $608.49 on Thursday. The stock’s fifty day moving average is $532.33 and its two-hundred day moving average is $532.45. The company has a market capitalization of $26.10 billion, a PE ratio of 21.77, a price-to-earnings-growth ratio of 4.35 and a beta of 0.49. United Therapeutics has a 52 week low of $432.53 and a 52 week high of $614.23.

Insiders Place Their Bets

In other news, EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $544.30, for a total transaction of $4,517,690.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $24,587,119.60. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $596.22, for a total transaction of $5,664,090.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $193,439,405.46. The trade was a 2.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 393,228 shares of company stock worth $207,340,321. Insiders own 8.60% of the company’s stock.

United Therapeutics declared that its board has initiated a share buyback plan on Thursday, October 22nd that allows the company to repurchase $2 billion in outstanding shares. This buyback authorization allows the biotechnology company to buy up to 8.3% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Third-quarter revenue rose 4.1% year over year to $832.5 million, beating analyst expectations of about $781 million. The earnings-call coverage also pointed to management’s view that the company is entering a period of stronger growth. Third-quarter results Earnings call highlights
• Positive Sentiment: BTIG raised its price target to $768 from $728 and reiterated a Buy rating, indicating confidence in UTHR’s potential despite the earnings shortfall. BTIG analyst action
• Positive Sentiment: The company announced a buydown of a Pfizer royalty tied to ralinepag, its pulmonary hypertension therapy. The deal could improve UTHR’s share of the therapy’s economics, although the provided reports do not specify the financial terms. Ralinepag royalty announcement
• Negative Sentiment: Adjusted earnings were $5.71 per share, below consensus estimates (reported at roughly $5.85–$6.01), and down from $7.16 a year earlier. The earnings miss and year-over-year decline in profit temper the revenue beat. Earnings miss report

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Morgan Stanley increased their target price on shares of United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. Royal Bank Of Canada lowered their target price on shares of United Therapeutics from $708.00 to $697.00 and set an “outperform” rating for the company in a report on Thursday, October 22nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $728.00 price target on shares of United Therapeutics in a research note on Wednesday, October 14th. Bank of America cut their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, Leerink Partners upped their price target on shares of United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a report on Monday, October 19th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $674.00.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.